hoodb.com

輝瑞成人RSV疫苗獲FDA批准;三星生物再簽12億美元大單;羅氏放棄UCB 1.2億美元阿茲海默症Tau抗體療法開發

|

You are leaving and open the following URL" of about "rsv" news

news.google.com/rss/articles/CBMiaEFVX3lxTE03eFhVLWNTYXczc2lncHRLQXdMdHdIbFEzV1dCVzN6RVpscXVLbEx6UTFPS3RxZ2l1cld1LXV1VVo4aU9EUWJpR3c2Q0otV0dnQ05jVV9aN0FlQ2lKQUhYYTZyOE5UQ1Yy?oc=5


Continue Opne >

rsv: 輝瑞成人RSV疫苗獲FDA批准;三星生物再簽12億美元大單;羅氏放棄UCB 1.2億美元阿茲海默症Tau抗體療法開發


More rsv news:


1735286372-1735279908

About rsv

from
1735286373-1735066450

Warning: filemtime(): stat failed for aCache/search/no/rsv in /var/www/hoodb/function.php on line 339
1735286373-

rsv, 輝瑞成人RSV疫苗獲FDA批准;三星生物再簽12億美元大單;羅氏放棄UCB 1.2億美元阿茲海默症Tau抗體療法開發 2022 rsv

輝瑞成人RSV疫苗獲FDA批准;三星生物再簽12億美元大單;羅氏放棄UCB 1.2億美元阿茲海默症Tau抗體療法開發

Choose Your Country or Region


Back to Top



輝瑞成人RSV疫苗獲FDA批准;三星生物再簽12億美元大單;羅氏放棄UCB 1.2億美元阿茲海默症Tau抗體療法開發

Copyright © 2020-2021 hoodb.com. All Rights Reserved.